No Data
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Regulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy Rating
Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429
Regulus Therapeutics GAAP EPS of -$0.21 Misses by $0.04
Regulus Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Regulus Therapeutics Q3 Income From Operations USD -15.21 Million
No Data
No Data